Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | CA6 | P23280 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17946064 | 0.90 | MEN1 (0.47) | RXFP1MEN1KMT2ACYP3A4CA12 | |
| SCHEMBL10354178 | 0.84 | MEN1 (0.46) | RXFP1MEN1KMT2ACYP3A4CA12 | |
| SCHEMBL987150 | 0.83 | LMNA (0.45) | MEN1KMT2ACYP3A4CA12CA1 | |
| SCHEMBL11789059 | 0.83 | PKM (0.67) | MEN1KMT2ACYP3A4CA12CA1 | |
| SCHEMBL219096 | 0.83 | TUBB4A (0.55) | MEN1KMT2ACYP3A4LMNATSHR | |
| SCHEMBL28275397 | 0.83 | TUBB4A (0.55) | MEN1KMT2ACYP3A4LMNATSHR | |
| SCHEMBL11855711 | 0.83 | CYP3A4 (0.45) | RXFP1MEN1KMT2ACYP3A4CA12 | |
| SCHEMBL985988 | 0.81 | TSHR (0.44) | MEN1KMT2ACYP3A4CA12CA1 | |
| SCHEMBL12331341 | 0.81 | CA12 (0.44) | RXFP1MEN1KMT2ACYP3A4CA12 | |
| SCHEMBL27189392 | 0.81 | LMNA (0.44) | RXFP1MEN1KMT2ACYP3A4CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109668987-A | A kind of 3- amino piperidine dihydrochloride enantiomter measurement analysis method | 浙江华贝药业有限责任公司 | 2019-04-23 | — | — | CN | claimed |
| EP-3357904-B1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | PRECIGEN INC (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-3357904-B1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | PRECIGEN INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20200270225-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2020-08-27 | — | — | US | disclosed |
| US-10633361-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2020-04-28 | — | — | US | disclosed |
| US-10633361-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2020-04-28 | — | — | US | disclosed |
| EP-3219204-B1 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | INTREXON CORP (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-3219204-B1 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | INTREXON CORP (US) | 2019-08-07 | — | — | EP | disclosed |
| CN-109668987-A | A kind of 3- amino piperidine dihydrochloride enantiomter measurement analysis method | 浙江华贝药业有限责任公司 | 2019-04-23 | — | — | CN | disclosed |
| CN-105018509-B | Mutant receptors and their applications in the inducible gene expression system based on nuclear receptor | 因特莱克森公司 | 2019-03-05 | — | — | CN | disclosed |
| US-20050266457-A1 | Modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms | INTREXON CORPORATION | 2005-12-01 | — | — | US | disclosed |
| WO-2005108617-A2 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | RHEOGENE,INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| EP-1553075-A1 | LPA RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004078924-A2 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| EP-1032561-B1 | SUBSTITUTED OXIMES AS NEUROKININ ANTAGONISTS | SCHERING CORP (US) | 2004-02-11 | — | — | EP | disclosed |
| US-6369070-B1 | Methods for inhibiting mrp1 | ELI LILLY AND COMPANY | 2002-04-09 | — | — | US | disclosed |
| EP-1032561-A1 | SUBSTITUTED OXIMES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 2000-09-06 | — | — | EP | disclosed |
| US-6063926-A | HAVING GREATER BIOACTIVITY | SCHERING CORPORATION (US) | 2000-05-16 | — | — | US | disclosed |
| WO-1999026924-A1 | SUBSTITUTED OXIMES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1999-06-03 | — | — | WO | disclosed |
| WO-1998007722-A1 | QUATERNARY AMMONIUM COMPOUNDS AS TACHYKININ ANTAGONIST | PFIZER LIMITED (GB) | 1998-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050266457-A1 | Modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms | NR2E3, HAVCR2, FCER2 | RXFP1 2035/4885MEN1 4765/4885KMT2A 663/4885 |
| US-20200270225-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, CRYZ, TCF12 | RXFP1 1971/4885MEN1 2893/4885KMT2A 1191/4885 |
| US-10633361-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | NR2E3, CRYZ, TCF12 | RXFP1 1971/4885MEN1 2893/4885KMT2A 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.